


REMARKS

By the foregoing amendment to the specification, the applicants have provided a statement of related applications at page 1 of the specification, and amended the specification to remove inadvertent references to h2520-109. In addition, the applicants have corrected obvious typographical errors.

By the foregoing amendment to the claims, the applicants have canceled claims 1-8, 10-11, 15, 19-39, 46-48, 51-57, and 59-66, and amended claims 9, 12-14, 16-17, and 42 to remove reference to SEQ ID NO: 4, such that the amended claims are drawn to a polypeptide comprising the sequence set forth in SEQ ID NO: 2 and a method of use thereof. The present amendments are made without prejudice to the applicants' right to pursue original claims at a later date. The claims pending upon entry of the instant amendment correspond to the subject matter of the claims of Group III as identified in the office action mailed January 31, 2002 in parent patent application, U.S. Serial No. 09/724,126. No new matter has been added. Claims 9, 12-14, 16-18, 40-45, 49-50, and 58 will be pending upon entry of the instant amendment.

Dated: January 15, 2004

Respectfully submitted,

By 
Lynn L. Danulis, PhD

Registration No.: 53,066
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicants